Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 34 results.
User Information
Export Records
  1. 1.   Crystal structure of a novel Kunitz type inhibitor, alocasin with anti-Aedes aegypti activity targeting midgut proteases
  2. Vajravijayan, Senthilvadivel; Pletnev,Sergei; Pletnev, Vladimir Z.; Nandhagopal, Narayanasamy; Gunasekaran, Krishnasamy
  3. PEST MANAGEMENT SCIENCE. 2018, DEC; 74(12): 2761-2772.
  1. 2.   Genotypic Resistance at Viral Rebound Among Patients Who Received Lopinavir/Ritonavir-Based or Efavirenz-Based First Antiretroviral Therapy in South Africa
  2. Dlamini, J. N.; Hu, Z. H.; Ledwaba, J.; Morris, L.; Maldarelli, F. M.; Dewar, R. L.; Highbarger, H. C.; Somaroo, H.; Sangweni, P.; Follmann, D. A.; Pau, A. K.; Phidisa, I. I. S. T.
  3. Jaids-Journal of Acquired Immune Deficiency Syndromes. 2011, Nov; 58(3): 304-308.
  1. 3.   Crystal structures of the free and inhibited forms of plasmepsin I (PMI) from Plasmodium falciparum
  2. Bhaumik, P.; Horimoto, Y.; Xiao, H. G.; Miura, T.; Hidaka, K.; Kiso, Y.; Wlodawer, A.; Yada, R. Y.; Gustchina, A.
  3. Journal of Structural Biology. 2011, Jul; 175(1): 73-84.
  1. 4.   Identification of a Potential Pharmacological Sanctuary for HIV Type 1 in a Fraction of CD4(+) Primary Cells
  2. Valentin, A.; Morrow, M.; Poirier, R. H.; Aleman, K.; Little, R.; Yarchoan, R.; Pavlakis, G. N.
  3. Aids Research and Human Retroviruses. 2010, Jan; 26(1): 79-88.
  1. 5.   Suboptimal inhibition of protease activity in human immunodeficiency virus type 1: Effects on virion morphogenesis and RNA maturation
  2. Moore, M. D.; Fu, W.; Soheilian, F.; Nagashima, K.; Ptak, R. G.; Pathak, V. K.; Hu, W. S.
  3. Virology. 2008 379(1): 152-160.
  1. 6.   Site-specific mutations in HIV-1 gp41 reveal a correlation between HIV-1-mediated bystander apoptosis and fusion/hemifusion
  2. Garg, H.; Joshi, A.; Freed, E. O.; Blumenthal, R.
  3. Journal of Biological Chemistry. 2007, Jun; 282(23): 16899-16906.
  1. 7.   Prednisolone pharmacokinetics in the presence and absence of Ritonavir after oral prednisone administration to healthy volunteers
  2. Penzak, S. R.; Fomnentini, E.; Alfaro, R. M.; Long, M.; Natarajan, V.; Kovacs, J.
  3. Jaids-Journal of Acquired Immune Deficiency Syndromes. 2005, DEC 15; 40(5): 573-580.
  1. 8.   Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A
  2. Witvrouw, M.; Fikkert, V.; Hantson, A.; Pannecouque, C.; O'Keefe, B. R.; McMahon, J.; Stamatatos, L.; De Clercq, E.; Bolmstedt, A.
  3. Journal of Virology. 2005, JUN; 79(12): 7777-7784.
  1. 9.   A novel and efficient approach to discriminate between pre- and post-transcription HIV inhibitors
  2. Daelemans, D.; Pannecouque, C.; Pavlakis, G. N.; Tabarrini, O.; De Clercq, E.
  3. Molecular Pharmacology. 2005, MAY; 67(5): 1574-1580.
  1. 10.   CD40 ligand dysregulation in HIV infection: HIV glycoprotein 120 inhibits signaling cascades upstream of CD40 ligand transcription
  2. Zhang, R.; Fichtenbaum, C. J.; Hildeman, D. A.; Lifson, J. D.; Chougnet, C.
  3. Journal of Immunology. 2004 172(4): 2678-2686.
  1. 11.   Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes
  2. Penzak, S. R.; Shen, J. M.; Alfaro, R. M.; Remaley, A. T.; Natarajan, V.; Falloon, J.
  3. Therapeutic Drug Monitoring. 2004 26(3): 322-330.
  1. 12.   Action of Anti-HIV drugs and resistance: Reverse transcriptase inhibitors and protease inhibitors
  2. Imamichi, T.
  3. Current Pharmaceutical Design. 2004 10(32): 4039-4053.
  1. 13.   Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen
  2. Polis, M. A.; Suzman, D. L.; Yoder, C. P.; Shen, J. A.; Mican, J. M.; Dewar, R. L.; Metcalf, J. A.; Falloon, J.; Davey, R. T.; Kovacs, J. A.; Feinberg, M. B.; Masur, H.; Piscitelli, S. C.
  3. Aids. 2003 17(8): 1167-1172.
  1. 14.   Antiviral and immunological benefits in HIV patients receiving intranasal peptide T (DAPTA)
  2. Polianova, M. T.; Ruscetti, F. W.; Pert, C. B.; Tractenberg, R. E.; Leoung, G.; Strang, S.; Ruff, M. R.
  3. Peptides. 2003 24(7): 1093-1098.
  1. 15.   Structure-based design of AIDS drugs and the development of resistance
  2. Wlodawer, A.
  3. Vox Sanguinis. 2002 83(Suppl. 1): 23-26.
  1. 16.   Protease inhibitor-induced stabilization of p21(waf1/cip1) and cell-cycle arrest in chemical carcinogen-exposed mammary and lung cells
  2. Khan, Q. A.; Dipple, A.; Anderson, L. M.
  3. Molecular Carcinogenesis. 2002 33(1): 1-8.
  1. 17.   Rational approach to AIDS drug design through structural biology
  2. Wlodawer, A.
  3. Annual Review of Medicine. 2002 53: 595-614.
  1. 18.   Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters
  2. Dybul, M.; Chun, T. W.; Yoder, C.; Hidalgo, B.; Belson, M.; Hertogs, K.; Larder, B.; Dewar, R. L.; Fox, C. H.; Hallahan, C. W.; Justement, J. S.; Migueles, S. A.; Metcalf, J. A.; Davey, R. T.; Daucher, M.; Pandya, P.; Baseler, M.; Ward, D. J.; Fauci, A. S.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2001 98(26): 15161-15166.
  1. 19.   Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy
  2. O'Brien, T. R.; McDermott, D. H.; Ioannidis, J. P. A.; Carrington, M.; Murphy, P. M.; Havlir, D. V.; Richman, D. D.
  3. Aids. 2000 14(7): 821-826.
  1. 20.   The aspartic proteinase from Saccharomyces cerevisiae folds its own inhibitor into a helix
  2. Li, M.; Phylip, L. H.; Lees, W. E.; Winther, J. R.; Dunn, B. M.; Wlodaawer, A.; Kay, J.; Gustchina, A.
  3. Nature Structural Biology. 2000 7(2): 113-117.
  1. 21.   High-level resistance to 3 '-azido-3 '-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1
  2. Imamichi, T.; Sinha, T.; Imamichi, H.; Zhang, Y. M.; Metcalf, J. A.; Falloon, J.; Lane, H. C.
  3. Journal of Virology. 2000 74(2): 1023-1028.
  1. 22.   Cloning of the bovine leukemia virus proteinase in Escherichia coli and comparison of its specificity to that of human T-cell leukemia virus proteinase
  2. Zahuczky, G.; Boross, P.; Bagossi, P.; Emri, G.; Copeland, T. D.; Oroszlan, S.; Louis, J. M.; Tozser, J.
  3. Biochimica et Biophysica Acta - Protein Structure & Molecular Enzymology. 2000 1478(1): 1-8.
  1. 23.   Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain
  2. Sei, S.; Yang, Q. E.; O'Neill, D.; Yoshimura, K.; Nagashima, K.; Mitsuya, H.
  3. Journal of Virology. 2000 74(10): 4621-4633.
  1. 24.   Papuamides A-D, HIV-inhibitory and cytotoxic depsipeptides from the sponges Theonella mirabilis and Theonella swinhoei collected in Papua New Guinea
  2. Ford, P. W.; Gustafson, K. R.; McKee, T. C.; Shigematsu, N.; Maurizi, L. K.; Pannell, L. K.; Williams, D. E.; de Silva, E. D.; Lassota, P.; Allen, T. M.; van Soest, R.; Andersen, R. J.; Boyd, M. R.
  3. Journal of the American Chemical Society. 1999 121(25): 5899-5909.
  1. 25.   Parallel evolution of drug resistance in HIV: Failure of nonsynonymous/synonymous substitution rate ratio to detect selection
  2. Crandall, K. A.; Kelsey, C. R.; Imamichi, H.; Lane, H. C.; Salzman, N. P.
  3. Molecular Biology and Evolution. 1999 16(3): 372-382.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel